These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36448876)

  • 21. Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A single-center study.
    Ebian HF; Elshorbagy S; Mohamed H; Embaby A; Khamis T; Sameh R; Sabbah NA; Hussein S
    Cancer Biomark; 2021; 32(3):379-389. PubMed ID: 34487021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pattern and prognostic value of FLT3-ITD mutations in Chinese de novo adult acute myeloid leukemia.
    Liu SB; Qiu QC; Bao XB; Ma X; Li HZ; Liu YJ; Chen SN; Song YH; Wu DP; Xue SL
    Cancer Sci; 2018 Dec; 109(12):3981-3992. PubMed ID: 30320942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [FMS-like tyrosine kinase 3 gene mutations in acute myeloid leukemia].
    Han YL; Zhang SJ; Qiao C; Dai D; Sun XM; Xu YL; Qian SX; Xu W; Wang JS; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1135-9. PubMed ID: 19840437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in
    Sharawat SK; Raina V; Kumar L; Sharma A; Bakhshi R; Vishnubhatla S; Gupta R; Bakhshi S
    Indian J Med Res; 2016 May; 143(Supplement):S11-S16. PubMed ID: 27748272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of KIT and FLT3-ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission.
    Wang J; Dao FT; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ; Jiang Q; Qin YZ
    Hematol Oncol; 2022 Oct; 40(4):724-733. PubMed ID: 35531760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML.
    Buelow DR; Pounds SB; Wang YD; Shi L; Li Y; Finkelstein D; Shurtleff S; Neale G; Inaba H; Ribeiro RC; Palumbo R; Garrison D; Orwick SJ; Blachly JS; Kroll K; Byrd JC; Gruber TA; Rubnitz JE; Baker SD
    Clin Transl Sci; 2019 Nov; 12(6):641-647. PubMed ID: 31350825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognosis predictive value of FMS-like tyrosine kinase 3-internal tandem duplications mutant allelic ratio (FLT3-ITD MR) in patients with acute myeloid leukemia detected by GeneScan.
    Lyu M; Liao H; Shuai X; Jin Y; Su J; Zheng Q
    Gene; 2020 Feb; 726():144195. PubMed ID: 31669649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia.
    Liang DC; Shih LY; Hung IJ; Yang CP; Chen SH; Jaing TH; Liu HC; Chang WH
    Cancer; 2002 Jun; 94(12):3292-8. PubMed ID: 12115363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Flt-3/ITD mutation in pediatric leukemia and its clinical significance].
    Wang J; Wang T; Li S; Lin L; Gang Y
    Ai Zheng; 2007 Jan; 26(1):58-63. PubMed ID: 17222369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FLT3-ITD and CD135 Over-Expression are Frequent Findings of Poor Survival in Adult Patients with Acute Leukemias.
    Vela-Ojeda J; Cardenas PV; Garcia-Ruiz Esparza MA; Montiel Cervantes LA; Chavez JG; Caballero AH; Majluf-Cruz A; Vega-López A; Reyes-Maldonado E
    Arch Med Res; 2021 Feb; 52(2):217-223. PubMed ID: 33109387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.
    Staffas A; Kanduri M; Hovland R; Rosenquist R; Ommen HB; Abrahamsson J; Forestier E; Jahnukainen K; Jónsson ÓG; Zeller B; Palle J; Lönnerholm G; Hasle H; Palmqvist L; Ehrencrona H;
    Blood; 2011 Nov; 118(22):5905-13. PubMed ID: 21967978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.
    Wang L; Xu WL; Meng HT; Qian WB; Mai WY; Tong HY; Mao LP; Tong Y; Qian JJ; Lou YJ; Chen ZM; Wang YG; Jin J
    J Zhejiang Univ Sci B; 2010 Oct; 11(10):762-70. PubMed ID: 20872983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medium-sized FLT3 internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort.
    Koszarska M; Meggyesi N; Bors A; Batai A; Csacsovszki O; Lehoczky E; Adam E; Kozma A; Lovas N; Sipos A; Krahling T; Dolgos J; Remenyi P; Fekete S; Masszi T; Tordai A; Andrikovics H
    Leuk Lymphoma; 2014 Jul; 55(7):1510-7. PubMed ID: 24090502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of FLT3 internal tandem duplication in egyptian patients with acute myeloid leukemia with normal or favorable risk cytogenetics.
    Shahin D; Aly R; Ebrahim MA
    Egypt J Immunol; 2010; 17(2):23-32. PubMed ID: 23082484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.
    Tiribelli M; Geromin A; Michelutti A; Cavallin M; Pianta A; Fabbro D; Russo D; Damante G; Fanin R; Damiani D
    Cancer; 2011 May; 117(10):2156-62. PubMed ID: 21523728
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Barajas JM; Umeda M; Contreras L; Khanlari M; Westover T; Walsh MP; Xiong E; Yang C; Otero B; Arribas-Layton M; Abdelhamed S; Song G; Ma X; Thomas Rd ME; Ma J; Klco JM
    Haematologica; 2024 Aug; 109(8):2459-2468. PubMed ID: 38426285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wilms' tumor protein and FLT3-internal tandem duplication expression in patients with de novo acute myeloid leukemia.
    Spassov BV; Stoimenov AS; Balatzenko GN; Genova ML; Peichev DB; Konstantinov SM
    Hematology; 2011 Jan; 16(1):37-42. PubMed ID: 21269566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
    Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
    Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.